{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:26:24Z","timestamp":1790047584363,"version":"4.0.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002425"],"award-info":[{"award-number":["82002425"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010097","name":"China Association for Science and Technology","doi-asserted-by":"publisher","award":["YESS20200011"],"award-info":[{"award-number":["YESS20200011"]}],"id":[{"id":"10.13039\/100010097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.tranon.2021.101309","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T07:04:27Z","timestamp":1639033467000},"page":"101309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Chimeric antigen receptor T cells targeting CD147 for non-small cell lung cancer therapy"],"prefix":"10.1016","volume":"16","author":[{"given":"Xiao-Hong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruo-Fei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Qian","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Nan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.tranon.2021.101309_bib0001","first-page":"452","article-title":"Cancer statistics for adults aged 85 years and older, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.tranon.2021.101309_bib0002","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.tranon.2021.101309_bib0003","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.tranon.2021.101309_bib0004","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-Small Cell Lung Cancer: epidemiology, Screening, Diagnosis, and Treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.tranon.2021.101309_bib0005","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/978-1-0716-0146-4_14","article-title":"Immunophenotypic analysis of CAR-T cells","volume":"2086","author":"de Azevedo","year":"2020","journal-title":"Methods Mol. Biol."},{"issue":"12","key":"10.1016\/j.tranon.2021.101309_bib0006","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2021.101309_bib0007","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: proposals for revision of the tnm stage groupings in the forthcoming (Eighth) edition of the TNM Classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"10066","key":"10.1016\/j.tranon.2021.101309_bib0008","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","article-title":"Lung cancer: current therapies and new targeted treatments","volume":"389","author":"Hirsch","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.tranon.2021.101309_bib0009","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1634\/theoncologist.2008-0261","article-title":"Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions","volume":"14","author":"Morabito","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.tranon.2021.101309_bib0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu. Rev. Med."},{"issue":"5","key":"10.1016\/j.tranon.2021.101309_bib0011","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/resp.12789","article-title":"Immunotherapy for lung cancer","volume":"21","author":"Steven","year":"2016","journal-title":"Respirology"},{"issue":"2","key":"10.1016\/j.tranon.2021.101309_bib0012","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.tranon.2021.101309_bib0013","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","author":"June","year":"2018","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.tranon.2021.101309_bib0014","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.tranon.2021.101309_bib0015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","article-title":"Programming CAR-T cells to kill cancer","volume":"2","author":"Labanieh","year":"2018","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.tranon.2021.101309_bib0016","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-018-0677-2","article-title":"Universal CARs, universal T cells, and universal CAR T cells","volume":"11","author":"Zhao","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2021.101309_bib0017","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00262-020-02735-0","article-title":"Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives","volume":"70","author":"Qu","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.tranon.2021.101309_bib0018","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev-med-051914-021702","article-title":"CAR-T Cell therapy for lymphoma","volume":"67","author":"Ramos","year":"2016","journal-title":"Annu. Rev. Med."},{"issue":"13","key":"10.1016\/j.tranon.2021.101309_bib0019","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-18-2559","article-title":"Combined CD28 and 4-1BB costimulation potentiates affinity-tuned chimeric antigen receptor-engineered T Cells","volume":"25","author":"Drent","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2021.101309_bib0020","doi-asserted-by":"crossref","first-page":"32804","DOI":"10.1038\/srep32804","article-title":"CD147\/EMMPRIN overexpression and prognosis in cancer: a systematic review and meta-analysis","volume":"6","author":"Xin","year":"2016","journal-title":"Sci. Rep."},{"issue":"19","key":"10.1016\/j.tranon.2021.101309_bib0021","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.2174\/0929867321666131227163352","article-title":"CD147: a novel modulator of inflammatory and immune disorders","volume":"21","author":"Zhu","year":"2014","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.tranon.2021.101309_bib0022","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s12265-015-9608-6","article-title":"Function of CD147 in atherosclerosis and atherothrombosis","volume":"8","author":"Wang","year":"2015","journal-title":"J. Cardiovasc. Transl. Res."},{"issue":"2","key":"10.1016\/j.tranon.2021.101309_bib0023","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19020507","article-title":"Extracellular matrix metalloproteinase inducer EMMPRIN (CD147) in cardiovascular disease","volume":"19","author":"von Ungern-Sternberg","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.tranon.2021.101309_bib0024","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1586\/14737140.2015.1092874","article-title":"The roles of CD147 in the progression of gliomas","volume":"15","author":"Fei","year":"2015","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"2","key":"10.1016\/j.tranon.2021.101309_bib0025","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ijrobp.2005.12.034","article-title":"Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I\/II trials","volume":"65","author":"Chen","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.tranon.2021.101309_bib0026","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1158\/1535-7163.MCT-14-0104","article-title":"Preclinical pharmacokinetics, tolerability, and pharmacodynamics of metuzumab, a novel CD147 human-mouse chimeric and glycoengineered antibody","volume":"14","author":"Zhang","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"W1","key":"10.1016\/j.tranon.2021.101309_bib0027","doi-asserted-by":"crossref","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"12","key":"10.1016\/j.tranon.2021.101309_bib0028","doi-asserted-by":"crossref","first-page":"e82241","DOI":"10.1371\/journal.pone.0082241","article-title":"Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer","volume":"8","author":"Gy\u0151rffy","year":"2013","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.tranon.2021.101309_bib0029","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13059-016-1028-7","article-title":"Comprehensive analyses of tumor immunity: implications for cancer immunotherapy","volume":"17","author":"Li","year":"2016","journal-title":"Genome Biol."},{"issue":"21","key":"10.1016\/j.tranon.2021.101309_bib0030","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","article-title":"TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.tranon.2021.101309_bib0031","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41392-021-00677-2","article-title":"CD147 receptor is essential for TFF3-mediated signaling regulating colorectal cancer progression","volume":"6","author":"Cui","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.tranon.2021.101309_bib0032","unstructured":"Di-methylation of CD147-K234 Promotes the Progression of NSCLC by Enhancing Lactate Export."},{"issue":"11","key":"10.1016\/j.tranon.2021.101309_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111803","article-title":"CD147 is a promising target of tumor progression and a prognostic biomarker","volume":"11","author":"Landras","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"29","key":"10.1016\/j.tranon.2021.101309_bib0034","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.2174\/1381612823666170710144759","article-title":"Targeting CD147 is a novel strategy for antitumor therapy","volume":"23","author":"Lian","year":"2017","journal-title":"Curr. Pharm. Des."},{"issue":"12","key":"10.1016\/j.tranon.2021.101309_bib0035","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1038\/s41375-019-0615-5","article-title":"CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives","volume":"33","author":"Mohty","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.tranon.2021.101309_bib0036","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrclinonc.2013.46","article-title":"Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors","volume":"10","author":"Kochenderfer","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tranon.2021.101309_bib0037","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/5019367","article-title":"CD147 as a novel prognostic biomarker for hepatocellular carcinoma: a meta-analysis","volume":"2017","author":"Peng","year":"2017","journal-title":"Biomed. Res. Int."},{"issue":"9","key":"10.1016\/j.tranon.2021.101309_bib0038","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju239","article-title":"Randomized trial of [131I] metuximab in treatment of hepatocellular carcinoma after percutaneous radiofrequency ablation","volume":"106","author":"Bian","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"15","key":"10.1016\/j.tranon.2021.101309_bib0039","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-18-1538","article-title":"Immunotherapy in non-small cell lung cancer: facts and hopes","volume":"25","author":"Doroshow","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"7689","key":"10.1016\/j.tranon.2021.101309_bib0040","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.tranon.2021.101309_bib0041","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","article-title":"Driving CAR T-cells forward","volume":"13","author":"Jackson","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.tranon.2021.101309_bib0042","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.tranon.2021.101309_bib0043","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11684-019-0684-x","article-title":"Adoptive cell transfer therapy for hepatocellular carcinoma","volume":"13","author":"Zhang","year":"2019","journal-title":"Front. Med."},{"issue":"12","key":"10.1016\/j.tranon.2021.101309_bib0044","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.tranon.2021.101309_bib0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41568-020-0273-y","article-title":"Metabolism of immune cells in cancer","author":"Leone","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.tranon.2021.101309_bib0046","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41591-020-0821-8","article-title":"Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid\/rhabdoid tumors","volume":"26","author":"Theruvath","year":"2020","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.tranon.2021.101309_bib0047","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","article-title":"Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.tranon.2021.101309_bib0048","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.tranon.2021.101309_bib0049","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1042\/BST20150291","article-title":"Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy","volume":"44","author":"Yeku","year":"2016","journal-title":"Biochem. Soc. Trans."},{"issue":"1","key":"10.1016\/j.tranon.2021.101309_bib0050","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol. Rev."},{"issue":"8","key":"10.1016\/j.tranon.2021.101309_bib0051","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"issue":"8","key":"10.1016\/j.tranon.2021.101309_bib0052","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.tranon.2021.101309_bib0053","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1053\/j.seminoncol.2015.05.015","article-title":"Anticancer cytokines: biology and clinical effects of interferon-\u03b12, Interleukin (IL)-2, IL-15, IL-21, and IL-12","volume":"42","author":"Floros","year":"2015","journal-title":"Semin. Oncol."},{"issue":"10","key":"10.1016\/j.tranon.2021.101309_bib0054","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","article-title":"Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2021.101309_bib0055","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40425-017-0230-9","article-title":"Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment","volume":"5","author":"Scarf\u00f2","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tranon.2021.101309_bib0056","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","article-title":"Tumor microenvironment and therapeutic response","volume":"387","author":"Wu","year":"2017","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.tranon.2021.101309_bib0057","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523321003004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523321003004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:28:39Z","timestamp":1778833719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523321003004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":57,"alternative-id":["S1936523321003004"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2021.101309","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric antigen receptor T cells targeting CD147 for non-small cell lung cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2021.101309","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101309"}}